ERBB2 and breast cancer: Collectively, these results indicate that SG offers superior improvements in PFS and OS over chemotherapy regimens from physicians, not only for patients with relapsed or refractory mTNBC who have limited treatment options and poor prognoses but also for heavily pretreated patients with ET‐resistant HR+/HER2− BC.